IBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
iBio Inc (IBIO) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks clear positive catalysts, has weak financial performance, and no strong trading signals or recent news to support a buy decision. Holding or avoiding the stock is recommended at this time.
The MACD is slightly positive but contracting, RSI is neutral at 48.341, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its pivot level (2.097), with limited upside potential based on resistance levels (R1: 2.258, R2: 2.357). Short-term trend analysis suggests a slight negative bias with a 70% chance of a -0.04% change in the next day and -1.03% in the next week.
The company's extended half-life antibody platform targeting obesity and metabolic indications has potential, as highlighted by analysts. Bullish moving averages provide some technical support.
There is no recent news or significant trading trends from insiders or hedge funds. Additionally, the stock lacks strong AI trading signals or congress trading activity.
In Q2 2026, revenue dropped to 0 (-100% YoY), net income improved to -$8.993M (+106.07% YoY), and EPS fell to -0.3 (-37.50% YoY). Gross margin remained at 100%. Overall, financials indicate poor growth and profitability.
JonesResearch initiated coverage with a Buy rating and a $7 price target, citing potential in the company's antibody platform. However, clinical data is over 12 months away, and the stock's movement is expected to correlate with INHBE siRNA companies. Piper Sandler raised a price target for ImmunityBio, but this is unrelated to IBIO.
